MTOR and neoplasm: AKT inhibitors such as AKT-inhibitor-VIII, MK-2206 (O'Donnell et al., 2018), A-443654 (Han et al., 2007), and PI3K inhibitors such as GDC-0941 (Haagensen et al., 2012) can inhibit the PI3K-AKT-mTOR signaling pathway, thereby inhibiting tumor progression.